JP2025503704A - Ｖｅｇｆ及びｔｉｅ２を結合する融合タンパク質並びにその使用 - Google Patents

Ｖｅｇｆ及びｔｉｅ２を結合する融合タンパク質並びにその使用 Download PDF

Info

Publication number
JP2025503704A
JP2025503704A JP2024542028A JP2024542028A JP2025503704A JP 2025503704 A JP2025503704 A JP 2025503704A JP 2024542028 A JP2024542028 A JP 2024542028A JP 2024542028 A JP2024542028 A JP 2024542028A JP 2025503704 A JP2025503704 A JP 2025503704A
Authority
JP
Japan
Prior art keywords
fusion protein
identity
seq
vegf
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024542028A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503704A5 (https=
Inventor
チュ，ミンキュン
キム，クワンス
ハン，サンヨル
ドゥロスト，フィリップ
Original Assignee
インゲニア・セラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インゲニア・セラピューティクス・インコーポレイテッド filed Critical インゲニア・セラピューティクス・インコーポレイテッド
Publication of JP2025503704A publication Critical patent/JP2025503704A/ja
Publication of JP2025503704A5 publication Critical patent/JP2025503704A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024542028A 2022-01-13 2023-01-12 Ｖｅｇｆ及びｔｉｅ２を結合する融合タンパク質並びにその使用 Pending JP2025503704A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263299177P 2022-01-13 2022-01-13
US63/299,177 2022-01-13
US202263310359P 2022-02-15 2022-02-15
US63/310,359 2022-02-15
US202263335805P 2022-04-28 2022-04-28
US63/335,805 2022-04-28
PCT/US2023/060582 WO2023137395A1 (en) 2022-01-13 2023-01-12 Vegf and tie2-binding fusion protein and uses thereof

Publications (2)

Publication Number Publication Date
JP2025503704A true JP2025503704A (ja) 2025-02-04
JP2025503704A5 JP2025503704A5 (https=) 2025-05-02

Family

ID=87279731

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024542028A Pending JP2025503704A (ja) 2022-01-13 2023-01-12 Ｖｅｇｆ及びｔｉｅ２を結合する融合タンパク質並びにその使用

Country Status (16)

Country Link
US (1) US20230287109A1 (https=)
EP (1) EP4463482A4 (https=)
JP (1) JP2025503704A (https=)
KR (1) KR20250005053A (https=)
AU (1) AU2023206363A1 (https=)
CA (1) CA3242904A1 (https=)
CL (2) CL2024002106A1 (https=)
CO (1) CO2024010934A2 (https=)
CR (1) CR20240342A (https=)
DO (1) DOP2024000136A (https=)
GE (1) GEAP202416581A (https=)
IL (1) IL314219A (https=)
JO (1) JOP20240158A1 (https=)
MX (1) MX2024008737A (https=)
PE (1) PE20260003A1 (https=)
WO (1) WO2023137395A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025178471A1 (ko) * 2024-02-20 2025-08-28 주식회사 맵틱스 Tie2 및 vegf에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210155697A1 (en) * 2019-11-21 2021-05-27 Unity Biotechnology, Inc. Antibodies directed to tie-2 and methods of use
JP2021526801A (ja) * 2018-06-07 2021-10-11 インスティテュート・フォー・ベイシック・サイエンスＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂａｓｉｃ Ｓｃｉｅｎｃｅ 抗Ｔｉｅ２抗体およびその使用
JP2022502367A (ja) * 2018-09-24 2022-01-11 エアーピオ ファーマシューティカルズ， インコーポレイテッド ＨＰＴＰ−β（ＶＥ−ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX359833B (es) * 2011-08-19 2018-10-12 Regeneron Pharma Anticuerpos anti-tie2 y usos de los mismos.
JP2020501508A (ja) * 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
US10597453B2 (en) * 2018-06-29 2020-03-24 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
AU2021242249A1 (en) * 2020-03-24 2022-08-18 Genentech, Inc. Tie2-binding agents and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021526801A (ja) * 2018-06-07 2021-10-11 インスティテュート・フォー・ベイシック・サイエンスＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂａｓｉｃ Ｓｃｉｅｎｃｅ 抗Ｔｉｅ２抗体およびその使用
JP2022502367A (ja) * 2018-09-24 2022-01-11 エアーピオ ファーマシューティカルズ， インコーポレイテッド ＨＰＴＰ−β（ＶＥ−ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体
US20210155697A1 (en) * 2019-11-21 2021-05-27 Unity Biotechnology, Inc. Antibodies directed to tie-2 and methods of use

Also Published As

Publication number Publication date
WO2023137395A1 (en) 2023-07-20
CL2025002473A1 (es) 2025-11-14
CL2024002106A1 (es) 2025-03-28
JOP20240158A1 (ar) 2024-07-14
PE20260003A1 (es) 2026-01-06
MX2024008737A (es) 2024-09-11
EP4463482A4 (en) 2026-05-06
CO2024010934A2 (es) 2024-10-31
CR20240342A (es) 2024-09-18
US20230287109A1 (en) 2023-09-14
EP4463482A1 (en) 2024-11-20
IL314219A (en) 2024-09-01
AU2023206363A1 (en) 2024-08-15
KR20250005053A (ko) 2025-01-09
CA3242904A1 (en) 2025-03-14
GEAP202416581A (en) 2024-12-10
DOP2024000136A (es) 2024-10-15

Similar Documents

Publication Publication Date Title
JP7314356B2 (ja) 改変ｊ鎖を有する結合分子
EP3733715A1 (en) Triabody, preparation method and use thereof
JP7102670B2 (ja) 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合
CN114341189A (zh) 全新il-15前药及其应用
US20250051413A1 (en) Chimeric molecules comprising il-12 agonist polypeptide
WO2019080872A1 (zh) 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途
KR20100128291A (ko) Ｅｇｆｒ에 결합하는 조작된 단백질을 기초로 하는 표적화된 치료제
JP2022028654A (ja) Ｖｅｇｆ－ｇｒａｂタンパク質と薬物の結合体及びその用途
CN114901691A (zh) Ilt3结合剂及其使用方法
JP2021515538A (ja) 自己免疫疾患を治療するための抗ｉｆｎａｒ１抗体
CN115925977B (zh) 双特异性融合多肽及其应用
TW202134277A (zh) Ｎ—端ｓｃＦｖ多特異性結合分子
JP2025523049A (ja) 抗Ｎｅｃｔｉｎ－４抗体及びその使用
JP2023533042A (ja) Ｉｌ－１２及び抗ｆａｐ抗体を含む融合タンパク質、並びにその使用
JP7270944B1 (ja) 抗ｃａｄｍ１抗体またはその抗原結合断片
CN117529494A (zh) 包括il-12激动剂多肽的嵌合分子
JP2025503704A (ja) Ｖｅｇｆ及びｔｉｅ２を結合する融合タンパク質並びにその使用
US9644031B2 (en) Epidermal growth factor receptor antibody
CA3226537A1 (en) Humanized anti-human .beta.ig-h3 protein and uses thereof
CN114656567A (zh) 抗icos抗体及其应用
EP4559932A1 (en) Multispecific antibody and use thereof
KR20250168499A (ko) 액티빈 a 수용체 유사 유형 1(alk1)에 대한 이중 특이적 효현성 항체
HK40118737A (zh) 结合vegf和tie2的融合蛋白及其用途
CN118922443A (zh) 结合VEGF和Tie2的融合蛋白及其用途
WO2025070337A1 (ja) 抗ＭｅｒＴＫアゴニスト抗体、抗ＭｅｒＴＫ二重特異性抗体、及びその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250423

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260403